About Us

Company Overview

Cardiol Therapeutics is a clinical-stage life sciences company focused on the research and clinical development of cannabidiol as an anti-inflammatory and anti-fibrotic therapy for the treatment of cardiovascular diseases

The Company brings together a wealth of research and development experience, advanced manufacturing capabilities, and a Management team, Board of Directors, and Scientific Advisory Board comprising business and thought leaders with extensive industry experience and expertise in commercializing prescription medicines. Learn more…

Cardiol’s lead product candidate, CardiolRx™, is a pharmaceutically produced oral cannabidiol formulation that is being clinically developed for use in cardiovascular medicine. Learn more…

CardiolRx is currently being evaluated in a Phase II/III multi-national, randomized, double-blind, placebo-controlled study (the LANCER trial). LANCER is designed to evaluate the safety and efficacy of CardiolRx™ as a cardioprotective therapy to reduce major cardiovascular and respiratory events and improve symptoms in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, CVD, and to investigate the impact of CardiolRx™ on key cardiac and inflammatory biomarkers. It is now recognized that the impact of SARS-CoV-2 infection that causes COVID-19 is not limited to the pulmonary system. People who have had COVID-19 have an increased risk and burden for adverse cardiovascular outcomes (such as acute myocardial infarction, dysrhythmias, pulmonary embolism, pericarditis, myocarditis, stroke, and heart failure) up to one year following their COVID-19 diagnosis. Learn more… 

The Corporation has also received Investigational New Drug Application (“IND”) authorization from the United States Food and Drug Administration (“FDA”) to conduct a Phase II multi-national, randomized, double-blind, placebo- controlled trial designed to evaluate the efficacy and safety of CardiolRx™ in acute myocarditis. This disease remains an important cause of acute and fulminant heart failure and is a leading cause of sudden cardiac death in people less than 35 years of age. The Corporation believes there is a significant opportunity to develop CardiolRx™ as an orphan drug for the treatment of acute myocarditis, for which there is currently no accepted standard of care. Learn more…

The Corporation has also received an IND authorization by the FDA to conduct a Phase II open-label pilot study designed to evaluate the tolerance and safety of CardiolRx™ in patients with recurrent pericarditis. The study will also assess the improvement in objective measures of disease, and during an extension period, assess the feasibility of weaning concomitant background therapy including corticosteroids while taking CardiolRx™. Recurrent pericarditis is the most common of pericardial diseases with symptoms that include debilitating chest pain, shortness of breath, and fatigue.  Further, up to 50% of patients with a recurrent episode of pericarditis experience more recurrences. Recurrent pericarditis is an orphan disease in the United States, thereby making CardiolRx™ eligible for orphan drug status under the FDA’s Orphan Drug Designation program. Learn more…

In addition, the Corporation is developing a subcutaneous cannabidiol formulation targeting the inflammation and fibrosis associated with the development and progression of heart failure. Heart failure is a chronic, progressive condition estimated to affect 64 million globally and is a leading cause of death and hospitalization, with associated annual healthcare costs in the U.S. alone exceeding $30 billion. Learn more…